false
0001630212
0001630212
2026-10-14
2026-10-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
October 14, 2026
Change Agents Corporation
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-38728 |
|
47-1685128 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I. R. S. Employer
Identification No.) |
4400 Route 9 South, Suite 3100
Freehold, NJ 07728
(Address of principal executive offices, including
ZIP code)
(732) 780-4400
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common stock, $0.0001 par value |
|
CHGA |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On October 14, 2026, Change
Agents Corporation (the “Company”) appointed Eric Weisblum as an independent director
on the Company’s board of directors, effective October 12, 2026. Mr. Weisblum will serve on each of the Audit, Compensation and
Nominating and Corporate Governance Committees.
Eric
Weisblum brings decades of investment banking, capital markets and public company management experience. Since 2020 Mr. Weisblum has
been the Chief Executive Officer of Silo Pharma Inc, a biopharmaceutical company that he founded. Prior to Silo Pharma Mr. Weisblum
was a private investor, board member, and advisor to several companies. Mr. Weisblum has experience in both licensing therapeutic
assets and assisting in their development. As a result, Mr. Weisblum brings with him nearly 20 years of experience in structuring
and trading financial instruments. Mr. Weisblum was a registered representative with Domestic Securities, a New Jersey-based
broker-dealer. While with Domestic Securities, Mr. Weisblum held the Series 7 - General Securities Representative, the Series 63
– Uniform Securities Agent State Law Examination, and the Series 55 – Registered Equity Trader securities registrations.
From 1993 to 2002, Mr. Weisblum originated, structured, traded, and placed structured financing transactions at M.H. Meyerson &
Co. Inc., a publicly-traded registered investment bank. He holds a B.A. from the University of Hartford’s Barney School of
Business.
The Company believes Mr. Weinblum is suited to act as a Company Director due to his significant public company and capital markets experience.
There
is no arrangement or understanding between Mr. Weisblum and any other person, other than the Company’s directors acting solely
in their capacity as such, pursuant to which he was selected as a director of the Company. Mr. Weisblum is not related by blood, marriage
or adoption to any director or executive officer.
The
Company is not aware of any transaction, or currently proposed transaction, in which the Company was or is to be a participant and in
which Mr. Weisblum, or any member of his immediate family, had or will have a direct or indirect material interest that would be required
to be reported under Item 404(a) of Regulation S-K.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| Date: October 16, 2026 |
Change Agents Corporation |
| |
|
| |
/s/ Sam Knipper |
| |
Sam Knipper |
| |
Chief Financial Officer |
